Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Platelet inhibitors: old and new].

Thomas Lecompte1

  • 1Université Henri Poincaré Nancy-1, EA 3452-CHU de Nancy, service d'hématologie biologique, France.

La Tunisie Medicale
|April 18, 2003
PubMed
Summary

Platelet inhibiting drugs, like aspirin and clopidogrel, prevent arterial thrombosis in atherosclerosis. Newer drugs target platelet aggregation mechanisms, offering options for coronary artery disease patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

How to monitor and manage unfractionated heparin in practice (Part 1)? Guidance from the SSC of the ISTH.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Evaluating Four HIT Prediction Scores After Cardiac Surgery With Cardiopulmonary Bypass: A Comparative Study.

Journal of cardiothoracic and vascular anesthesia·2026
Same author

Quantitative Flow Cytometry-Medical Applications with a Focus on Blood Platelets.

International journal of molecular sciences·2026
Same author

Activated Protein C Sensitivity Assessed with Thrombin Generation Assay in Antiphospholipid Syndrome Women: Results from Two French Cohorts.

Thrombosis and haemostasis·2026
Same author

Thromboelastometric assessment of the haemostatic effect of tranexamic acid as an adjunct to prophylactic platelet transfusions in patients with haematological malignancies undergoing intensive chemotherapy: A pilot study.

Vox sanguinis·2025
Same author

Laboratory Monitoring of UFH in Different Settings (DEXHEP Study): Association between Anti-Xa Levels, Platelet Factor 4 (PF4) Plasma Levels and Dextran Sulfate.

Thrombosis and haemostasis·2025

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Hematology

Background:

  • Platelet inhibiting drugs are crucial for preventing arterial thrombosis associated with atherosclerosis.
  • Extensive clinical trials have established clear indications and international guidelines for their use.
  • Aspirin's mechanism, inhibiting thromboxane synthesis, shows a strong correlation between molecular pharmacology and clinical outcomes.

Purpose of the Study:

  • To review the mechanisms and applications of recently developed platelet inhibiting drugs.
  • To highlight novel antiplatelet agents beyond aspirin.
  • To discuss their role in managing patients with active coronary artery disease.

Main Methods:

  • Review of existing clinical trial data and pharmacological studies.
  • Description of the mechanisms of action for aspirin, clopidogrel, and glycoprotein IIb/IIIa inhibitors.
  • Analysis of current clinical guidelines and therapeutic applications.

Main Results:

  • Aspirin inhibits platelet thromboxane synthesis, with well-defined clinical correlations.
  • Clopidogrel, a thienopyridine, irreversibly blocks ADP-mediated platelet activation via the P2Y12 receptor.
  • Glycoprotein IIb/IIIa inhibitors block fibrinogen binding, a key step in platelet aggregation.

Conclusions:

  • Newer antiplatelet agents offer advanced therapeutic options for arterial thrombosis.
  • Clopidogrel and glycoprotein IIb/IIIa inhibitors are valuable additions to aspirin therapy in coronary artery disease.
  • Understanding drug mechanisms enhances clinical application and patient outcomes in atherosclerosis management.

Related Experiment Videos